

OPEN ACCESS JOURNAL AT INIST-CNRS

Gene Section

Mini Review

ADIPOR1 (adiponectin receptor 1)

Virginia Kaklamani, Christos Mantzoros

Department of Medicine, Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL, 676 N St Clair St. Suite 850, Chicago, IL 60611, USA (VK); Department of Medicine, Division of Endocrinology, Harvard University Medical School, Beth Israel Deaconess Medical Center, E/St 816, 330 Brookline Ave, Boston, MA02215, USA (CM)

Published in Atlas Database: May 2009

Online updated version: http://AtlasGeneticsOncology.org/Genes/ADIPOR1ID44512ch1q32.html DOI: 10.4267/2042/44724

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2010 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Other names: ACDCR1; CGI-45; CGI45; FLJ25385 FLJ42464; PAQR1; TESBP1A

HGNC (Hugo): ADIPOR1

Location: 1q32.1

DNA/RNA

Description

Eight exons spanning 17.5 kb. Transcription is from telomere to centromere.

Transcription

Transcription produces 11 different mRNAs, 10 alternatively spliced variants and 1 unspliced form. There are 6 probable alternative promoters, 2 non overlapping alternative last exons and 8 validated alternative polyadenylation sites. The mRNAs appear to differ by truncation of the 5' end, truncation of the 3' end, presence or absence of 6 cassette exons, overlapping exons with different boundaries. 9 spliced and the unspliced mRNAs putatively encode good proteins, altogether 9 different isoforms (3 complete, 6 partial), some containing Hly-III related proteins domain (Pfam) some transmembrane domains (Psort2); 1 of the 3 complete proteins appears to be secreted. The remaining mRNA variant (spliced) appears not to encode a good protein.

Protein

Description

Receptor for globular and full-length adiponectin (APM1), an essential hormone secreted by adipo-cytes that counteracts the effects of insulin.

Expression

Widely expressed. Highly expressed in adipose tissue and skeletal muscle. Expressed at intermed-iate level in brain, heart, spleen, kidney, liver, placenta, lung and peripheral blood leukocytes. Weakly expressed in colon, thymus and small intestine. We have also shown expression in normal and cancerous breast tissue as well as in other cancers such as prostate, colon, endometrial. It is also present in several cell lines.

Localisation

ADIPOR1 localizes to the plasma membrane.

Function

Receptor for globular and full-length adiponectin (APM1), an essential hormone secreted by adipo-cytes that acts as an antidiabetic. Probably involved in metabolic pathways that regulate lipid meta-bolism such as fatty acid oxidation. Mediates increased AMPK, PPARa ligand activity, fatty acid oxidation and glucose uptake by adiponectin. Has some high-affinity for globular adiponectin but low-affinity for full-length adiponectin.



Genomic structure of ADIPOR1. Blue boxes indicate exons.

Homology

The mouse, human, and rat Adipor1 protein (ADIPOR1) contains 375 amino acids. Human and mouse ADIPOR1 share 96.8% identity.

Mutations

Note

One functional polymorphism has been described. Rs7539542 has been found to modulate expression of ADIPOR1 mRNA (Soccio et al., 2006).

Implicated in

Breast Cancer

Note

Adiponectin has been implicated in breast cancer. The breast cancer cell lines MCF-7, MDB-MB-231 and T47D were found to express both adiponectin receptors ADIPOR1/ADIPOR2 (Dieudonne et al., 2006; Korner et al., 2007) and exposure of T47D cells to adiponectin, significantly inhibited their proliferation (Korner et al., 2007). rs2232853 CT genotype (OR=1.67; 95% CI 1.23-2.26) and the combination of rs7539542 GC (OR=0.59; 95% CI 0.36-0.98) and CC genotypes (OR=0.57; 95% CI 0.35-0.94) were significantly associated with breast cancer risk. The high expressing rs2241766 G allele (GG and GT genotypes) was associated with decreased breast cancer risk (OR=0.64; 95% CI 0.49-0.83). The low expressing rs1501299 G allele was associated with increased breast cancer risk: for TG: OR=1.59; 95% CI 1.03-2.48, for GG: OR= 1.80; 95% CI 1.14-2.85.

Colon Cancer

Note

Adiponectin has also been implicated in colon cancer risk. rs266729 polymorphism was signi-ficantly associated with colon cancer risk: the RR for the GG/CG genotypes was rs266729 was associated with a reduced colorectal cancer risk: O.R. 0.73, 95% CI (0.53-0.99) (Kaklamani et al., 2008).

Endometrial Cancer

Note

Adiponectin levels have been shown to correlate with endometrial cancer risk (Petridou et al., 2003; Dal et al., 2004).

Prostate Cancer

Note

Adiponectin levels have been shown to correlate with prostate cancer risk (Barb et al., 2007; Arisan et al., 2009).

References

Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, Chrousos G, Trichopoulos D. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab. 2003 Mar;88(3):993-7

Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La Vecchia C. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab. 2004 Mar;89(3):1160-3

Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2006 Jun 23;345(1):271-9

Soccio T, Zhang YY, Bacci S, Mlynarski W, Placha G, Raggio G, Di Paola R, Marucci A, Johnstone MT, Gervino EV, Abumrad NA, Klein S, Trischitta V, Doria A. Common haplotypes at the adiponectin receptor 1 (ADIPOR1) locus are associated with increased risk of coronary artery disease in type 2 diabetes. Diabetes. 2006 Oct;55(10):2763-70

Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2007 Sep;86(3):858-66

Körner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, Bullen J, Neuwirth A, Tseleni S, Mitsiades N, Kiess W, Mantzoros CS. Total and highmolecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab. 2007 Mar;92(3):1041-8

Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, Baron JA, Ahsan H, Mantzoros C, Pasche B. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA. 2008 Oct 1;300(13):1523-31

Arisan ED, Arisan S, Atis G, Palavan-Unsal N, Ergenekon E. Serum adipocytokine levels in prostate cancer patients. Urol Int. 2009;82(2):203-8

This article should be referenced as such:

Kaklamani V, Mantzoros C. ADIPOR1 (adiponectin receptor 1). Atlas Genet Cytogenet Oncol Haematol. 2010; 14(4):334-335.